#Hepatitis C pipeline

[healthcareporium]

Hepatitis C remains a significant global health concern, affecting millions worldwide with its chronic liver infection caused by the hepatitis C virus (HCV).

[colinwilson11]

The Rising Super Generics Market Driven By Increased Accessibility Of Affordable Medicines

Super generics are generic pharmaceutical drugs that are therapeutically equivalent to brand-name drugs but are significantly cheaper than both branded and ordinary generics. Super generics help overcome price barriers for patients living with chronic diseases by offering high-quality medicines at a fraction of brand-name drug costs. They are developed through a complex process involving developing robust generic drug applications with focus on matching active ingredients and treatment efficacy of reference drugs. The Super Generics Market is driven by the need to enhance access to medicines for a broader patient base while controlling increasing healthcare costs.

Key Takeaways

The Super Generics Marketis estimated to be valued at US$ 84 Bn in 2024 and is expected to exhibit a CAGR of 8.3% over the forecast period 2024-2031.

Key players operating in the super generics market are Accord Healthcare, Alcon Laboratories, Azurity Pharmaceuticals, Baxter, and Dr. Reddy’s Laboratories. These companies are focusing on expanding their generics drug portfolios and enhancing manufacturing scale to tap the high-growth super generics market segment.

The rising prevalence of chronic diseases and increasing healthcare costs are driving robust demand for more affordable generic drugs. Super generics are being preferred over ordinary generics as they provide nearly equivalent efficacy at 60-70% lower costs than reference drugs.

Technological advancements are helping super generics players develop robust generic equivalents of complex drugs and molecules. This is expanding treatment access in disease areas that were previously addressed only through expensive brand medications. Continuous innovations will remain crucial for market leadership.

Market Trends

Increasing approvals for complex generics - Regulatory agencies are promoting faster approvals for generic versions of complex drugs treating conditions like cancer, hepatitis C, and multiple sclerosis. This will significantly boost the super generics market.

Focus on specialty drug segments - Major players are developing robust portfolios targeting specialty drug categories like oncology, CNS disorders, and autoimmune diseases that dominate the prescription landscape. This represents a massive opportunity.

Market Opportunities

Opening of emerging markets - Markets in Latin America, Middle East, Africa, and Asia still rely majorly on on-patent branded drugs due lack of alternatives. increased super generics access can transform healthcare in these regions.

Partnerships for difficult-to-copy drugs - Companies are tying up with specialized players for technologies and know-how to develop low-cost versions of biologics and other difficult drugs, presenting a long growth runway.

Impact Of COVID-19 On Super Generics Market Growth

The COVID-19 pandemic has adversely impacted the super generics market growth. During the peak of the pandemic in 2020-2021, many manufacturing facilities were shut down momentarily due to lockdowns imposed by various governments. This led to disrupted supply chains and shortage of APIs (Active Pharmaceutical Ingredients). Many generics drug formulations also faced shortage issues. The demand for life-saving generics drugs saw a sharp rise during the pandemic. However, the supply could not keep up with such heightened demand levels. This mismatch negatively impacted the market revenues during these periods.

As the pandemic situation gradually stabilizes with declining infection rates worldwide, the super generics market is expected to bounce back strongly. The overall demand for affordable generics drugs remains high. Many new products are also in the pipeline for launch post-COVID. With resumption of normal operations across manufacturing facilities, the supply chains are getting restored. The easy availability of generics drugs will be crucial for universal healthcare during the post-COVID era. The market is anticipated to demonstrate accelerated growth trajectory from 2022 onwards to makeup for the pandemic disruptions.

Geographical Regions With Highest Value Concentration In Super Generics Market

North America accounts for the largest share of the Super Generics Market in terms of value. The U.S. market contributes significantly to the high revenue generation from the region. Low drug prices and patent expirations in the U.S. provide lucrative opportunities for super generics companies. Europe is another leading regional market, driven by favorable pricing policies and high acceptance of generics drugs across major countries like Germany, France, U.K, Spain, and Italy.

Fastest Growing Regional Market For Super Generics

Asia Pacific region is poised to showcase the fastest growth in the Super Generics Market over the forecast period from 2024 to 2031. The expanding patient population, rising healthcare spending, and ongoing initiatives to enhance healthcare access are fueling the market demand in Asia Pacific economies such as India, China, Australia, Japan, and South Korea. Significant investments by international generics drug makers to tap opportunities in the growth markets of Asia Pacific will further support the region’s growth momentum.

Get more insights on this topic:  https://www.trendingwebwire.com/the-super-generics-market-set-for-growth-due-to-advancements-in-bioavailability-enhancement-technologies/

 

Author Bio:

Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163 )

 

What Are The Key Data Covered In This Super Generics Market Report?

:- Market CAGR throughout the predicted period

:- Comprehensive information on the aspects that will drive the Super Generics Market's growth between 2024 and 2031.

:- Accurate calculation of the size of the Super Generics Market and its contribution to the market, with emphasis on the parent market

:- Realistic forecasts of future trends and changes in consumer behaviour

:- Super Generics Market Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa

:- A complete examination of the market's competitive landscape, as well as extensive information on vendors

:- Detailed examination of the factors that will impede the expansion of Super Generics Market vendors

FAQ’s

Q.1 What are the main factors influencing the Super Generics Market?

Q.2 Which companies are the major sources in this industry?

Q.3 What are the market’s opportunities, risks, and general structure?

Q.4 Which of the top Super Generics Market companies compare in terms of sales, revenue, and prices?

Q.5 Which businesses serve as the Super Generics Market’s distributors, traders, and dealers?

Q.6 How are market types and applications and deals, revenue, and value explored?

Q.7 What does a business area’s assessment of agreements, income, and value implicate?

*Note: 1. Source: Coherent Market Insights, Public sources, Desk research 2. We have leveraged AI tools to mine information and compile it

[helthcareheven]

A New Era of Healing: Transformative Infectious Disease Therapeutics

Infectious diseases have plagued mankind since antiquity. While public health improvements over the past century have helped control many infectious illnesses, new pathogens continue to emerge and existing ones adapt in the face of globalization and antimicrobial resistance. Researchers have made tremendous progress understanding the biology of infection and developing new therapeutic agents, but more work remains. This article outlines some of the latest advances in infectious disease therapeutics across different disease categories and research areas. Antibacterial Drug Development The rise of multidrug-resistant bacteria is a major public health crisis, and the dwindling antibiotic pipeline requires novel solutions. Several new classes of antibacterial agents are under development with activity against resistant pathogens. These include novel ß-lactams that evade extended-spectrum ß-lactamases and novel protein synthesis inhibitors that avoid ribosomal protection mechanisms. Phage therapy is also being revisited, with early clinical studies of engineered phages demonstrating safety and efficacy against difficult-to-treat infections like Pseudomonas aeruginosa and Acinetobacter baumannii. Alternative antibacterial platforms like antimicrobial peptides and small molecule inhibitors of virulence factors also show promise. Antiviral Drug Discovery While antibiotics face resistance challenges, antiviral drug development continues making progress against several important viral pathogens. Hepatitis C virus (HCV) represents a major success story, with over 90% cure rates now possible using direct-acting antiviral agents. Research on HIV continues as well, with newer integrase inhibitors and second-generation protease inhibitors demonstrating increased genetic barriers to resistance. Influenza remains a serious threat, but novel cap-dependent endonuclease inhibitors could provide the first truly universal flu drug. For other viruses like herpes simplex, respiratory syncytial virus (RSV) Pneumococcal Conjugate Vaccines Streptococcus pneumoniae (pneumococcus) is a leading cause of community-acquired pneumonia as well as invasive pneumococcal disease such as bacteremia and meningitis worldwide. The development of pneumococcal conjugate vaccines (PCVs) targeting the most prevalent disease-causing serotypes has substantially reduced the global burden of pneumococcal disease. PCV7 was first introduced in 2000 and dramatically cut rates of invasive pneumococcal disease in vaccinated children.

Malaria Control Efforts Malaria remains one of the leading infectious killers globally, with drug and insecticide resistance complicating control efforts. Important infectious disease therapeutics advances include the development of artemisinin-based combination therapies (ACTs) that help delay antimalarial resistance. Novel compounds also aim to complement ACTs through new mechanisms of action. These include the spiroindolone KAE609, which acts on the ATP4 transporter essential for parasite viability, and the Oz439 compound targeting the apicoplast organelle to block isoprenoid biosynthesis. Vaccine progress includes the RTS,S/AS01 candidate demonstrating promising reduction of malaria cases in young children in African clinical trials. Combined with improvements in diagnostics, vector control through insecticide-treated bed nets continues reducing malaria morbidity and mortality worldwide. Tuberculosis Treatment Mycobacterium tuberculosis resistance continues complicating tuberculosis (TB) treatment and control globally - about 20% of MDR-TB cases are estimated to further develop extensively drug-resistant TB (XDR-TB). New and repurposed drugs aim to shorten treatment duration for drug-sensitive TB from 6 months to 4 months or less. Regimens including pretomanid, bedaquiline, and delamanid demonstrate potential to treat both drug-sensitive and resistant TB in significantly less time than current guidelines. New anti-TB therapies also target mycobacterial virulence factors and pathways specific to the pathogen. Developing rapid diagnostics to detect drug resistance and evaluating optimized dosing regimens are additionally helping curb the global TB epidemic.

Novel Antifungal Therapies Life-threatening invasive fungal infections negatively impact public health worldwide, especially in immunocompromised patients. Current antifungal drug classes include azoles, echinocandins, and polyenes, but limitations include toxicities, drug interactions, emerging resistance, and lack of oral options for many serious mycoses. Novel therapies in development aim to overcome these challenges. Novel azoles target the sterol 14α-demethylase enzyme through different binding properties than existing drugs. Echinocandin follow-ups show activity against resistant Candida as well as Aspergillus species.

[newsheadlinesnow]

Hepatitis C Virus Infection Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, PMDA Approvals | GeneCure, Biotron, Cocrystal Pharma, Genecure, iQur, Dongguan, TaiGen

http://dlvr.it/Sv1Dpj

[impossibledeanmakerwombat]

Anti-Viral Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends And Forecast 2023 to 2032

The global anti-viral drugs market is expected to be valued at US$ 59,596.8 Million in 2022. The induction of the generic version of antiviral medicines and rising awareness about the availability of various vaccines for viral infections is affecting the growth throughout the forecast period. The overall demand for Anti-Viral Drugs is projected to grow at a CAGR of 3.9% between 2022 and 2032, totaling around US$ 87,675.36 Million by 2032.

Anti-viral drugs are medicines which are used specially for treating viral infections. Most anti-viral drugs are used for particular viral infections, similar to antibiotics, while a broad-spectrum anti-viral drug is effective against a varied range of viruses. Antiviral drugs do not kill their target pathogen, instead they inhibit the development of those viruses.

The global anti-viral drugs market is projected to register a moderate growth rate in the pharmaceutical market and which is anticipated to increase due to rise in awareness level, increase in the diseased population and introduction of new drugs with improved efficacy.

Some major patents are reaching their expiry during forecast period, such as for Combivir, Sustiva, Tenofovir, Tamiflu, Relenza and Telbivudine. The patent expiries of these blockbuster drugs is expected to trigger generic competition in the antivirals therapeutics market, which will make the market more competitive.

The late stage pipeline drugs are expected to enter the market, which will positively impact the market. Most antivirals are considered comparatively harmless to host, and therefore are used to treat infections. They are different from viricides, which are not used for medication but can destroy or deactivate virus particles, either outside or inside the body.

The anti-viral drugs are used in the treatment of patients suffering from herpes viruses, HIV, influenza A and B viruses and the hepatitis B and C viruses.

Request Sample Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-1951

Anti-viral Drugs Market: Drivers and Restraints

As of October 2013, according to WHO, there were around 35.3 Mn people globally, infected with HIV. Therefore, increased viral infection incidences is one of the important factors that drives the anti-viral drugs market growth. Because of the solid R&D activities, newer and advanced treatments and formulations, such as vaccines, combination therapy and others, are being introduced in the market.

Hence, strong R&D is one of the crucial factors in the anti-viral drugs market growth. On the other hand, high risk of failure, high cost of R&D and therapy, and government austerity are some of threats expected to hinder the growth of market.

These are some factors anticipated to fuel growth of global anti-viral drugs market within the forecast period of 2016-2026. However, increasing usage of natural products and high cost of developing drugs are the key challenges faced by the market.

Anti-viral Drugs Market: Overview

The generic market of anti-viral drugs is presently dominated by products such as didanosine, zidovudine, lamivudine and stavudine. The biggest driver of overall anti-viral drugs market is Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS) therapeutic sales which accounted for more than half the share of the market 2010.

At the end of 2012, 9.7 million people in low-income and middle-income countries were on antiretroviral treatment (ART). According to WHO, in 2012, number of patients on ART increased by 1.6 Mn, the largest increase in one year.

Nearly four out of five people were freshly put on treatment in the sub-Saharan Africa. In 21 African countries with a high burden of HIV, two out of three people in need are receiving treatment, and two out of three positive pregnant women are receiving antiretroviral drugs to prevent HIV transmission to their infants.

Ask For Customization @ https://www.futuremarketinsights.com/customization-available/rep-gb-1951

Anti-viral Drugs Market: Regional Overview

Region wise, the global anti-viral drugs market is classified into regions namely, North America, Eastern Europe, Western Europe, Latin America, Japan, Asia-Pacific, Middle East and Africa. According to WHO, in countries with Major ART scale-up such as Brazil or China, the death rate among people living with HIV has decreased by 80%. In 2015, in India the number of people living with HIV were 2.1 Mn and in U.S. the number was around 1.2 Mn in the year 2013.

Anti-viral Drugs Market: Key Players

Some of the key players in global anti-viral drugs market, which are focusing on general molecular mechanisms of antiviral drugs rather than therapies for individual viruses, include Roche, Gilead, GlaxoSmithKline, Bristol-Myers-Squibb, Abbott, AstraZeneca, Cipla, Schering-Plough, Johnson & Johnson, Merck & Co and others.

Key Segments Covered in the Anti-Viral Drugs Industry Analysis

Anti-Viral Drugs Market by Product type:

Hepatitis-C antivirals

HIV antivirals

Herpes antivirals

Hepatitis-B antivirals

Influenza antivirals

Others (Pneumonia, Flu, etc.)

Anti-Viral Drugs Market by End-user:

Hospitals

Clinics

Ambulatory Surgical Centers

Anti-Viral Drugs Market by Region:

North America Anti-Viral Drugs Market

Latin America Anti-Viral Drugs Market

Europe Anti-Viral Drugs Market

Asia Pacific Anti-Viral Drugs Market

The Middle East & Africa Anti-Viral Drugs Market

Ask An Analyst @ https://www.futuremarketinsights.com/ask-question/rep-gb-1951

[otcsocialnetwork]

Cocrystal Pharma Discusses Clinical Progress and Significance of Its Novel Antiv

The Stock Day Podcast welcomed Cocrystal Pharma, Inc. #Nasdaq $COCP (“Cocrystal,” “Cocrystal Pharma” or “the Company”), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), hepatitis C viruses and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs. Co-CEO and CFO of the Company Jim Martin joined Stock Day host Everett Jolly. Cocrystal Pharma Discusses Clinical Progress and Significance of Its Novel Antiviral Therapeutics Pipeline with The Stock Day Podcast The Stock Day Podcast welcomed Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal,” “Cocrystal Pharma” or “the Company”), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), hepatitis C viruses and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs. Check out our Free Penny Stock Screener HERE. http://dlvr.it/ShVycZ

[melbournenewsvine]

Vir Biotechnology to Participate in the H. C. Wainwright 3rd AnnualHepatitis B Virus (HBV) | News

SAN FRANCISCO, Oct. 11, 2022 (GLOBE NEWSWIRE) — Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Phil Pang, M.D., Ph.D., executive vice president, chief medical officer and interim head of research, is scheduled to present at the H. C. Wainwright 3rd Annual Hepatitis B Virus (HBV) Conference on Tuesday, October 18, at 10:30 a.m. PT / 1:30 p.m. ET. A live webcast of the fireside chat can be accessed under Events & Presentations in the Investors section of the Vir website at  www.vir.bio  and will be archived there for 30 days. About Vir Biotechnology Vir Biotechnology is a commercial-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of product candidates targeting COVID-19, hepatitis B and D viruses, influenza A and human immunodeficiency virus. Vir routinely posts information that may be important to investors on its website. Contact: Carly Scaduto Senior Director, Media Relations cscaduto@vir.bio +1-314-368-5189 Copyright 2022 GlobeNewswire, Inc. Source link Originally published at Melbourne News Vine

[harvonionline-blog]

Does Harvoni Costs Drop and covered by Medicare?

No reasonable cost of hepatitis C virus (HCV) medicine has generated remarkable strain for patients and the healthcare solutions. These drugs price as much as $95,000 for a 12-week therapy but pick a 90% or better cure ratio, which many believe rationalize the cost.

While few problems have included cost efficient strategies to stop early stage patients from getting the treatment, legal actions have been filed issuing the ethos of these practices.

Lawgivers are now issuing to build codification that will get these patients with the treatments they require but a legal age of scheme don’t boost traction, according to a report published by Mediware.

It received FDA approval in past and was the first drug consider secure and effective without interferon. It was also the first accepted corrective treatment for HCV.

No previous treatments follow outputted in a comforted viral diseases response, which made sofosbuvir a really sought-after drug. Gilead Sciences costly the treatment at $1K per pill, creating the total sum of the treatment $84K

Foul then integrate sofosbuvir with a new drug, ledipasvir to build the even more great combination treatment for a Buy Harvoni Online. Harvoni’s total bill pay approx. $95K for a 12 week procedure.

If CDC evaluate are accurate and 3.5 m Americans have   HCV, then therapy with Harvoni would cost payers $331 B which ware more than final amount drug expending in past year, according to say a report.

Although most other profession drugs only process a not a large number of patients, HCV drugs treat a large patient society and get manufacturers with great opportunities to product specific income.

Engaging, sofosbuvir enough costs $900 in Egypt, and $55,000 in Canada, considerably less than the cost in the US. This has generated some lawmakers to cite Gilead of cost gouging, and limiting manage to positive treatments, giving to the report.

Delightful, sofosbuvir only costs $900k in Egypt and $55 K in Canada, consider less than the cost in the US. This has generate some lawmakers to summons Gilead of cost delve and limiting manage to effective treatments, according to the report.

In some states, Medicaid receiver may not have equal preference to the medicines. US lawmaker have announced that some states cover 9.1% of soul for HCV treatment, while others only cover less than 1%.

Medicaid is unable to cover treatment for all medical, since covering 1 treatment with Harvoni prices the same as the yearly health care costs for 29 medical, which insights the requires for cost efficient, according to the analysis.

Both private and public insurers have had to create eligibility requirements that prioritize patients with liver damage, and those who have failed to respond to less costly treatments due to the high price of newer drugs. However, the Department of Veterans Affairs recently announced they would cover HCV treatment costs for all veterans as a result of increased funding and decreased drug costs, according to the report.

US President Donald Trump advising for lower medical costs, patients with HCV may boost explored manage to treatment.

Request such as providing Medicare cost conference, capping out-of-pocket drug prices, importing drugs, and limiting manufacturer’ expending on patient marketing could all output in lower HCV drug costs, the entrepreneur wrote.

Fighting has also been seen to smash HCV medicine costing, and will mostly continue to do so in the future as more drugs receive regulatory approval.

 The FDA’s oistive assign of Viekira Pak (ombitasvir, paritaprevir, and ritonavir drugs; dasabuvir tablets) in 2014 effected the pricing of Harvoni. The latest approval extract support from Express Scripts, who then fallen Harvoni and sofosbuvir for patients with HCV genotype 1.

Read more - 

What are the most common side effects of Harvoni?

 This output in Gilead’s stocks taking a 20% hit, assistance them to provide discounts for Harvoni to few money providers. If manufacturers get alike actions, medicine costs may be decreased even further.

 The most current approval of Merck’s Zepatier (elbasvir and grazoprevir) generated waves for many reasons. First, the drug’s cure rate was 97% to 100% in patients with HCV genotype 4, and 94% to 97% in patients with genotype 1, which is bigger compared with other medicines.

Remarkable, the cost for the medicine was only $54,600 for 12-weeks of routine, which improves manage to cost efficient, according to the report.

A pipeline drug, odalasvir, being build by Achillion medicament and Johnson & Johnson, also has the unique to decrease drug prices. The medicine has shown a 100% cure rate in as little as 6 weeks in combination with sofosbuvir. Not a huge treatment spans will mostly output in less costly drugs, the authors noted.

 Is $GILD's move to sell lower-priced versions of its hepatitis C drugs the start of something bigger in how we pay for drugs? @joewalkerWSJ explores the company's plans to sell authorized generics of Epclusa and Harvoni: https://t.co/QzusjKORX9

Despite treatment for HCV being health related to want, payers still do not think the high prices for the medicine warrant widespread treatment. However, critics may collector store that in the long run, payers are costing themselves more money.

 Patients who do not get treatment for HCV are more fairly to build liver cancer and kind 2 diabetes, experience plaque build-up in the arteries, and have an increased risk of stroke, according to the report.

 While Gilead’s drugs remain some of the highest priced on the market, the entrance of new, lower cost drugs will likely drive drop the price of HCV treatment over time?

 Until that happens, specialty pharmacies and their pharmacists should focus on directing patients to copay assistance programs, and help patients adhere to treatments, the report concluded.

[serosyndicatbloodunion]

ALTERNATE ENDINGS, ACTIVIST RISINGS | Résurgences activistes et d’autres fins possibles Programme de courts métrages sur l’activisme contemporain du milieu VIH/sida en Amérique All new 2018 videos from the iconic annual VisualAIDS project DAY WITH(OUT) ART by: ACT UP NY, Positive Women’s Network, Sero Project, The SPOT, Tacoma Action Collective, VOCAL NY Thurs.Jeudi.29.NOV.19H00 | FREE Concordia University Amphithéâtre du Pavillon EV 1e étage | 1515 rue Ste-Catherine Ouest, Montréal | local EV1.605 Biscuits + thé | Tea + cookies: 18H30; Film projection de films: 19H. Suivi d’une discussion animée par le | post-screening discussion hosted by: SéroSyndicat/BloodUnion.  

Event made possible by Karen Herland, Concordia University instructor for HIV/AIDS: An Interdisciplinary Introduction to Scientific Social and Cultural Aspects, part of the Interdisciplinary Studies in Sexuality Program

More on Visual AIDS: http://visualaids.org/projects/detail/alternate-endings-activist-risings La traduction des descriptions des films et du projet DAY WITH(OUT) ART sera disponible le 19 novembre seulement. From VISUALAIDS: ALTERNATE ENDINGS, ACTIVIST RISINGS is the 29th iteration of Visual AIDS’ longstanding Day With(out) Art project. Highlighting the impact of art in contemporary AIDS activism and advocacy, the program features new short videos from six inspiring community organizations and collectives—ACT UP NY, Positive Women’s Network, Sero Project, The SPOT, Tacoma Action Collective, and VOCAL NY. ALTERNTE ENDINGS, ACTIVIST RISINGS seeks to reflect the persisting urgencies of today’s HIV/AIDS epidemic, including HIV criminalization, Big Pharma, homelessness, and the disproportionate effects of HIV on marginalized communities. At a moment of growing interest in the histories of AIDS activism, ALTERNATE ENDINGS, ACTIVIST RISINGS foregrounds contemporary engagements between activists, artists, and cultural workers on the front lines.

RÉSURGENCES ACTIVISTES ET D’AUTRES FINS POSSIBLES souhaite souligner l’importance et l’impact de l’art sur l’activisme contemporain du milieu VIH/Sida nord-américain à travers un programme de courts-métrages récents provenant de six organismes communautaires et collectifs de premier plan: ACT UP NY, Positive Women’s Network, Sero Project, The SPOT, Tacoma Action Collective, et VOCAL NY. Le programme présente une sélection de stratégies organisationnelles diverses et variées, de l’action directe aux mouvements nationaux (américains) en passant par les prestataires de services communautaires, tout en incorporant l’importance des pratiques artistiques dans les réponses activistes face à la crise actuelle du sida.

RÉSURGENCES ACTIVISTES ET D’AUTRES FINS POSSIBLES met en lumière les urgences chroniques de l’épidémie de VIH/Sida contemporaine, notamment la criminalisation des personnes séropositives, le lobby des grands groupes pharmaceutiques, l’itinérance et les effets disproportionnés que le VIH a sur les communautés marginalisées. Alors qu’il existe un intérêt grandissants pour les histoires de l’activisme en milieu VIH, RÉSURGENCES ACTIVISTES ET D’AUTRES FINS POSSIBLES révèle les combats contemporains que portent les activistes, artistes et producteurs.trices d’art sur le terrain.

Films synopses and more on DAY WITH(OUT) ART: ALTERNATE ENDINGS, ACTIVIST RISINGS highlights the impact of art in AIDS activism and advocacy today by commissioning compelling short videos from six inspiring community organizations and collectives—ACT UP NY, Positive Women’s Network, Sero Project, The SPOT, Tacoma Action Collective, and VOCAL NY. The program represents a wide range of organizational strategies, from direct action to grassroots service providers to nation-wide movement building, while considering the role of creative practices in activist responses to the ongoing AIDS crisis. ALTERNATE ENDINGS, ACTIVIST RISINGS seeks to reflect the persisting urgencies of today’s HIV/AIDS epidemic by pointing to pressing and intersecting political concerns, including HIV criminalization, Big Pharma, homelessness, and the disproportionate effects of HIV on marginalized communities. At a moment of growing interest in the histories of AIDS activism, ALTERNATE ENDINGS, ACTIVIST RISINGS foregrounds contemporary engagements between activists, artists, and cultural workers on the front lines. Commissioned Organizations AIDS Coalition to Unleash Power (ACT UP) NY (New York, NY) is a diverse, non-partisan group of individuals, united in anger and committed to direct action to end the AIDS crisis. ACT UP was formed in 1987 in response to social neglect, government negligence and the complacency of the medical establishment during the 1980s. Soon it found itself needing to fight corporate greed, lack of solidarity and various forms of stigma and discrimination at home and abroad. ACT UP fights for: sustained investment in research for new medicines and treatments for HIV/AIDS and related co-infections; equitable access to prevention and care for HIV/AIDS and healthcare, in general; tackling the structural drivers of the HIV/AIDS epidemic, such as stigma, discrimination and poverty. Positive Women’s Network – USA (PWN) is a national membership body of women living with HIV and allies that exists to strengthen the strategic power of all women living with HIV in the United States. Founded in 2008 by 28 diverse women leaders living with HIV, PWN-USA develops a leadership pipeline and policy agenda that applies a gender lens to the domestic HIV epidemic grounded in social justice and human rights. Every day, PWN-USA inspires, informs and mobilizes women living with HIV to advocate for changes that improve lives and uphold rights. Sero Project is a national network of people with HIV and allies fighting for freedom from stigma and injustice. Sero is particularly focused on ending inappropriate criminal prosecutions of people with HIV, including for non-disclosure of their HIV status, potential or perceived HIV exposure or HIV transmission. Sero co-produces the biennial HIV is Not a Crime conference, which provides advocates from across the country with training on strategies and best practices for repealing laws that criminalize people living with HIV. Safe Place Over Time (The SPOT) (Jackson, MS) is dedicated to providing services and opportunities for wellness, empowerment, and leadership to young men in Jackson, Mississippi. The program aims to improve health outcomes and reduce new cases of HIV among African Americans who are disproportionately affected by the epidemic. The SPOT strives to be a safe place for young men to openly discuss issues and challenges and to work to improve their quality of life and to promote the concept of self-worth. The SPOT is housed in the Jackson Medical Mall, a former shopping mall that now provides healthcare for the underserved and promotes economic and community development. Tacoma Action Collective (Tacoma, WA) is a partnership of Black community organizers working in grassroots action and education in Washington State. TAC works to to eliminate systemic oppression and structural violence while empowering the people to build autonomous communities rooted in equity and justice. In 2015, the collective staged a die-in at the Tacoma Art Museum in response to the white-washing of the exhibition Art, AIDS, America. VOCAL (Voices Of Community Activists & Leaders) (New York, NY) is a statewide grassroots membership organization that builds power among low-income people affected by HIV/AIDS, hepatitis C, the drug war, homelessness, and mass incarceration in order to create healthy and just communities. VOCAL accomplishes this through community organizing, leadership development, public education, direct services, participatory research and direct action.

Texte traduit vers le français par Hugo B. pour le SéroSyndicat :

Organismes invités:

AIDS Coalition to Unleash Power (ACT UP) NY est groupe non partisan d’individus hétéroclites, unis dans la colère et résolus à prendre des actions directes afin d'éradiquer l’épidémie du sida. L’association ACT UP est née en 1987 en réponse au déni social, à la négligence du gouvernement et à la complaisance du secteur médical durant les années 80. Il fut rapidement évident et nécessaire qu’il leur faille également combattre l’avidité des grandes entreprises, le manque de solidarité face à la crise, ainsi que les différentes formes de stigmatisations et discriminations rencontrées à la fois aux État-Unis et à l’étranger.

ACT UP se bat pour: la mise en place d’investissements continus dans la recherche de nouveaux médicaments et traitements contre le VIH/Sida et ses co-infections sous-jacentes; un accès juste et équitable à la prévention contre le VIH/Sida, aux soins pour les personnes séropositives et séroconcernées, ainsi qu’au système de santé en général; l'éradication des facteurs structurels de l’épidémie du VIH/Sida, notamment la stigmatisation, les discriminations et la pauvreté.

Positive Women’s Network – USA (PWN) est un regroupement national (américain) de femmes vivant avec le VIH et leurs alliés.ées qui existe pour renforcer le pouvoir stratégique de toutes les femmes vivant avec le VIH aux États-Unis . Fondé en 2008 par 28 femmes leaders séropositives et venant d’horizons différents, PWN-USA développe un réseau de portes-paroles et un calendrier politique qui apporte un regard genré sur l’épidémie du VIH aux États-Unis dans une approche profondément ancrée dans la justice sociale et la défense des droits humains.

Chaque jour, PWN-USA inspire, informe et mobilise les femmes vivant avec le VIH en leur fournissant les outils et informations nécessaires pour qu’elles deviennent les leaders de changements qui améliorent les vies de toutes et protègent leurs droits.

  Sero Project est un réseau national de personnes vivant avec le VIH et leurs alliés.ées se battant pour l’affranchissement de toutes formes de stigmatisations et d’injustice. Sero travaille particulièrement à éliminer la criminalisation inappropriée des personnes vivant avec le VIH, que ce soit pour la non-divulgation de leur statut sérologique, l’exposition ou la transmission potentielles ou ressenties du VIH. Sero Project coproduit la biennale de conférences “HIV is Not a Crime” qui fournit aux acteurs.trices canadiens.ennes de la lutte contre le VIH des formations sur les stratégies et meilleures pratiques à employer pour critiquer et influencer un système judiciaire qui criminalise les personnes vivant avec le VIH.

 Safe Place Over Time (The SPOT) (Jackson, MS) se donne pour mission d’offrir des services et des opportunités aux jeunes hommes de Jackson, Mississippi, afin de renforcer leur bien-être, leur autonomisation et leur leadership. Le programme a pour but d’améliorer l’état de santé et de réduire les nouveaux cas de séroconversions au sein de la communauté afro-américaine qui est disproportionnellement affectée par l’épidémie. Le SPOT fait tout son possible pour être un endroit sécuritaire où les jeunes hommes peuvent discuter ouvertement des problèmes et difficultés auxquels ils font face afin d’améliorer leur qualité de vie et renforcer leur confiance en soi. Le SPOT est situé au sein même du Jackson Medical Mall, un ancien centre commercial qui offre aujourd’hui des services de santé aux communautés exclues et qui promeut le développement économique et communautaire.

 Tacoma Action Collective (Tacoma, WA) est un partenariat d’organisateurs communautaires noirs travaillant pour l’action et l’éducation citoyenne dans l’état de Washington. TAC cherche à éliminer l’oppression systémique et la violence structurelle auxquelles font face les communautés noires tout en renforçant leur capacité d’organisation communautaire autonome. L’action de TAC se veut profondément ancrée dans la justice et l’équité. En 2015, le collectif a orchestré un “die-in” au Tacoma Art Museum en réponse à l’invisibilisation des communautés noires au sein de l’exposition “AIDS, ART, AMERICA.”

 VOCAL (Voices Of Community Activists & Leaders) (New York, NY) est un organisme communautaire national américain qui renforce le pouvoir des personnes à faible revenu affectées par le VIH/Sida, par l’hépatite C, par la guerre contre les drogues, par l’itinérance ou encore, par l’incarcération de masse afin de créer des communautés justes et saines. VOCAL atteint ses objectifs à travers l’organisation et la lutte communautaire, le leadership, l’éducation publique, les services aux usagers, la recherche participative et l’action directe.

[kimoramorory]

Preliminary Testing Of New Drug Against Hepatitis C Shows Good Promise. Researchers are reporting that a medication is showing bond in early testing as a attainable new treatment for hepatitis C, a stubborn and potentially deadly liver ailment. It's too inappropriate to tell if the drug actually works, and it will be years before it's ready to seek federal okay to be prescribed to patients naturalhealthsource.shop. Still, the drug - or others like it in development - could tote to the power of new drugs in the pipeline that are poised to cure many more people with hepatitis C, said Dr Eugene R Schiff, cicerone of the University of Miami's Center for Liver Diseases. The greater prospect of a cure and fewer side effects, in turn, will lead more clan who think they have hepatitis C to "come out of the woodwork," said Schiff, who's familiar with the den findings. "They'll want to know if they're positive" health. An estimated 4 million masses in the United States have hepatitis C, but only about 1 million are thought to have been diagnosed. The disease, transmitted through infected blood, can cord to liver cancer, scarring of the liver, known as cirrhosis, and death. Existing treatments can working order about half of the cases. As Schiff explained, people's genetic makeup has a lot to do with whether they rejoin to the treatment neosizexlusa.shop. Those with Asian heritage do better, whereas those with an African qualifications do worse. And there's another potential problem with existing treatments. The side effects, solely of the treatment component known as interferon, can be "pretty hard to deal with," said Nicholas A Meanwell, a co-author of the scrutiny and a researcher with the Bristol-Myers Squibb pharmaceutical company. The study, published online April 21 in Nature, examines an hypothetical drug designed to combat the hepatitis C virus. It appears to knead by interfering with a protective coating around a part of the virus that's tonality to its ability to reproduce. In a phase 1 trial, the first of three types of studies that creative drugs must go through, researchers gave doses of the drug to a small number of people. The plane of the virus in their bodies dropped significantly for several days. The main side make was headache. At this point, it's not clear how much the drug might cost or how it would work with existing drugs. However it could become her of a combination treatment of several drugs. Schiff, the University of Miami doctor, said other companies are pursuing comparable drugs. For now, much of the attention in the world of liver disease is on two drugs - telaprevir and boceprevir - that Schiff expects will become at one's fingertips within the next year and a half. Combination treatments using these drugs will become the pedestal treatment for many people and boost cure rates into the range of 70 to 80 percent bengali. The drugs now under development, take a shine to the one in the new study, could be added to the regimen.

[healthcare-market]

Hepatitis Therapeutics Market Estimated to Record Highest CAGR by 2026

Transparency Market Research (TMR) has published a new report titled ‘Hepatitis Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026.’ According to the report, the global hepatitis therapeutics market was valued at US$ 22,049.2 Mn in 2017 and is projected to expand at a CAGR of 2.3% during forecast period from 2018 to 2026. The global market is anticipated to be driven by a rise in viraemic prevalence, promising pipeline of hepatitis drugs, and supportive government initiatives encouraging patients in the adoption of hepatitis drugs. The hepatitis therapeutics market in Asia Pacific is expected to expand at a high CAGR of 3.0%, due to a high incidence of hepatitis in emerging countries such as India and China and presence of local players providing a wide range of generic hepatitis drugs in the region.

Request a PDF Sample - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=52665

Increase in Prevalence of Viral Hepatitis Drives Market

Hepatitis is a significant public health concern across the globe. According to the World Health Organization (WHO), in 2015, approximately, 257 million people globally, or 3.5% of the population, were living with chronic hepatitis B infections. Rise in the consumption of alcohol, infections from contaminated blood sources, and increase in the number of autoimmune diseases are leading to a rise in the cases of inflammation of the liver. Viral hepatitis is an important source of morbidity and mortality globally. As per WHO estimates, viral hepatitis caused 1.34 million deaths in 2015, a number higher than the deaths caused by HIV. Additionally, mortality associated with viral hepatitis has increased by 22% since 2000, and the number is further expected to increase over the next few years. Hence, these factors are likely to boost demand for hepatitis therapeutics over the forecast period.

Request a PDF Brochure - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=52665

Hepatitis C Segment Dominated the Market

In terms of disease type, the global hepatitis therapeutics market has been classified into hepatitis A, hepatitis B, hepatitis C, and others. The hepatitis C segment is projected to account for a leading share of the global market during the forecast period, owing to the high prevalence of hepatitis C in developing and developed regions and availability of effective drug regimens in the market. According to the World Health Organization (WHO), approximately 71 million people were infected with chronic hepatitis C in 2017. Hepatitis C increases the risk of liver cirrhosis and is the leading cause of liver transplant in North America and Europe. Development of advanced therapeutics by leading industry players for the effective management of disease is expected to pave the way for the hepatitis C segment over the coming years. The hepatitis B segment is projected to expand at a rapid pace over the forecast period, owing to a high mortality rate associated with hepatitis B.

Request for Analysis of COVID19 Impact on Hepatitis Therapeutics Market- https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=52665

Multi-class Combination to be the Most Promising Segment to Invest in

Based on drug class, the global hepatitis therapeutics market has been segmented into NS5A inhibitors, nucleotide analog reverse transcriptase inhibitors, multi-class combination, nucleotide analog NS5B polymerase inhibitors, interferon & ribavirin, and others. The multi-class combination segment is projected to expand at a high CAGR during the forecast period, owing to an increase in viraemic prevalence worldwide. Industry players are focused on developing combinational therapy as it is highly effective and has fewer side-effects compared to a single regimen for the treatment of hepatitis C. Mavyret and Epclusa are some of the combinational therapeutics recently approved by the U.S. FDA.

Asia Pacific Market to Witness Strong Growth and Create High Incremental Opportunity

In terms of region, the global hepatitis therapeutics market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is anticipated to account for a leading share of the global market during the forecast period, owing to high awareness and access to advanced hepatitis therapeutics and high affordability of patients in the region. The hepatitis therapeutics market in Europe is expected to expand at a substantial rate between 2018 and 2026. The market in Asia Pacific is likely to expand at a rapid pace in the next few years. This is attributed to a growing patient population, increasing penetration of global manufacturers, and rising government initiatives to promote disease awareness in the region. The hepatitis therapeutics market in Latin America and Middle East & Africa is anticipated to expand at a steady pace from 2018 to 2026.

Enquiry before Buying Hepatitis Therapeutics Market Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=52665

Growth Strategies by Key Market Players

Key players profiled in this report are Merck & Co., Inc., Gilead Sciences, Inc., AbbVie Inc., Bristol Myers Squibb, F. Hoffmann-La Roche, Ltd., LAURUS Labs, Zydus Cadila, Hetero Healthcare Limited, NATCO Pharma Limited, and Cipla, Inc. Companies operating in the global hepatitis therapeutics market focus on R&D to develop innovative drugs used for the effective treatment of hepatitis. Market players also resort to strategic collaborations and license agreements with domestic players to expand their market foothold in developing countries.

More Trending Reports by Transparency Market Research:

About Us Section:

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyse information. Now avail flexible Research Subscriptions, and access Research multi-format through downloadable databooks, infographics, charts, interactive playbook for data visualization and full reports through MarketNgage, the unified market intelligence engine. Sign Up for a 7 day free trial!

Contact Us

Rohit Bhisey Transparency Market Research, 90 State Street, Suite 700, Albany, NY 12207 Tel: +1-518-618-1030 USA – Canada Toll Free: 866-552-3453 Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com/

[marketresearchindia]

Growth in Influenza (Flu) Antiviral Drugs Market research report : ken research

Buy Now

Global Influenza Antiviral Drugs Market Research Report contains strategic analysis of top grooming companies of the Influenza Medication market. The report reveals the emerging trends, market growth drivers, shares, revenue, and CAGR. It helps to understand the current and future growth of the market with restraints and opportunities. This report is aimed at guiding people towards an apprehensive, finer, and comprehensible knowledge of the market. The analysts have studied in the report about the different regions such as North America, Europe, and the Asia Pacific based on production, revenue, and sales.

According to the research report, “Global Influenza (Flu) Antiviral Drugs Industry Research Report 2021 Segmented by Major Market Players, Types, Applications and Countries Forecast to 2027”, influenza, also known as flu, is a respiratory disease caused by an influenza virus. Fever, cough, sore throat, cold are some of the common symptoms of the disorder. In temperate zones, this disease primarily occurs during winters while in tropical regions influenza may occur throughout the year. Severe complications of influenza can also develop a disease like pneumonia. For instance, in 2021, Gilead Sciences has signed licensing agreement with pharmaceutical manufacturers such as Cipla Ltd., Hetero Labs Ltd., Dr. Reddy's Laboratories Ltd., Mylan, and others to expand the supply of antiviral medicines.

Over the forecast period, the demand for antiviral drugs is growing due to the increasing viral infections across the globe. The global influenza medications market is divided into hospitals, clinics, pharmacies, and others. According to a study, an estimated million people are living with hepatitis infection and out of these, around half of the million have chronic hepatitis C virus infection. However, the prevalence of viral diseases has led to a striving growth in the market. Abbvie, Novartis AG, Gilead Sciences, Mylan N.V., Glaxo Smith, Kline Merck & Co., Janssen Pharmaceuticals, Bristol-Myers Squibb Company, are some of the prominent key players operating in the antiviral drugs market.

Request For Sample Report- https://kenresearch.com/sample-report.php?Frmdetails=NDQ0NzIw

In 2021, the market was valued at USD Million and is projected to reach to significant value in USD Million by the end of 2027. Moreover, the growth rate for the worldwide market is expected to grow at a single-digit CAGR by 2027. This growth is attributable to the presence of various key pharmaceutical companies in the U.S. In Latin America, the governments of Mexico and Brazil are taking persistent initiatives to manage viral infections, eventually increasing the generic pharmaceutical companies in the sector. On the other hand, countries such as India and Japan are establishing supply networks and enhancing pharmaceutical industries to accelerate the growth in this region.

The outbreak of the COVID-19 pandemic has positively affected the industry globally. The treatment of coronavirus has increased the demand for b antiviral drugs at a large scale. Remdesivir, favipiravir, oseltamivir, and other combination medicines are highly prescribed for the treatment of COVID-19. Moreover, governments, all over the world, are increasing funding to pharmaceutical companies to develop novel therapeutics against COVID-19.

Increasing collaborations for the development and manufacturing of antiviral drugs are expected to result in the development of a high number of novel drugs in the coming years. The presence of strong pipeline drugs for diseases like HIV will also fuel market growth over the forecast period. The key enterprises present in the market are constantly striving to bring about new treatment options for patients suffering from viral infections. Increasing approval and expected commercialization of novel medicines for viral infections are anticipated to drive market growth.

For More Information, refer to below link:-

Global Augmented Reality Automotive Market Research Report

Related Reports

2021-2027 Global and Regional Neuroprotective Products Industry Status and Prospects Professional Market Research Report Standard Version

2021-2027 Global and Regional Steam Chemical Indicator Industry Status and Prospects Professional Market Research Report Standard Version

Follow Us

LinkedIn | Instagram | Facebook | Twitter | YouTube

Contact Us:-

Ken Research                                                                                          

Ankur Gupta, Head Marketing & Communications

support@kenresearch.com

+91-9015378249

[fasefdnblt-blog]

바카라전략 소개해드리겠습니다

바카라전략 AsiaNetAbbott 제약사업 분사|- Two publicly traded companies will offer shareholder distinct opportunities given unique investment identities, business profiles and attributes- Builds on a decade of strategic and operational advancementsAsiaNet=46871(ABBOTT PARK, Ill., Oct. 20, 2011 AsiaNet=연합뉴스) Today Abbott (NYSE: ABT) announced that it plans to separate into two publicly traded companies, one in diversified medical products and the other in research-based pharmaceuticals. The diversified medical products company will consist of Abbott's existing diversified medical products portfolio, including its branded generic pharmaceutical, devices, diagnostic 바카라전략 and nutritional businesses, and will retain the Abbott name. The research-based pharmaceutical company will include Abbott's current portfolio of proprietary pharmaceuticals and biologics and will be named later. Both companies will be global leaders in their respective industries."Today's news is a significant event for Abbott, and reflects another dynamic change in our company's 123-year history, strengthening our outlook for strong and sustainable growth and shareholder returns," said Miles D. White, chairman and chief executive officer, Abbott.Abbott's proprietary pharmaceutical business has delivered market-leading performance with a sustainable mix of products and built a strong pipeline of proprietary medicines through internal discovery, in-licensing and 바카라전략 collaboration efforts. Abbott also has leadership positions in its diversified businesses, including established pharmaceuticals, nutritionals, diagnostics, and vascular devices, where the company is now the global leader in interventional cardiology.Creating Two Dynamic Health Care CompaniesThe research-based pharmaceutica 바카라전략l compa 바카라전략ny has nearly $18 billion in annual revenue today and will have a sustainable portfolio of market-leading brands, including Humira, Lupron, Synagis, Kaletra, Creon and Synthroid. An attractive pipeline of innovative R&D assets - in important specialty therapeutic areas such as Hepatitis C, immunology, chronic kidney disease, women's health, oncology and neuroscience - will help drive future growth.The diversified medical products company has approximately $22 billion in annual revenue today and a durable mix of products balanced across four major businesses. It will continue to target double-digit ongoing earnings-per-share growth, with opportunities for geographic expansion, particularly in high-growth emerging markets. The company will have an extensive, broad-based pipeline of new products and technologies as well as opportunities for significant margin expansion.Mr. White will remain chairman and CEO of Abbott, the diversified medical products company. Richard A. Gonzalez, currently executive vice president, Global Pharmaceuticals, will become chairman and CEO of the research-based pharmaceutical company. Mr. Gonzalez is a more than 30-year Abbott veteran and was previously president and chief operating officer of Abbott.Profiles of the Two CompaniesThe two companies have evolved into distinct investment and business opportunities:- The research-based pharmaceutical company will focus on select specialty products with breakthrough innovation that serve patient needs in some of the most critical medical areas, such as immunology, Multiple Sclerosis, chronic kidney disease, Hepatitis C, women's health and oncology. This company will continue to generate the majority of its revenue from developed markets. The company's sustainable portfolio and advancing pipeline, including established biologics expertise, have the potential to deliver accelerating revenue growth in the coming years.- The diversified medical products company will be one of the largest and fastest growing investment opportunities in medical products with strong sales and ongoing earnings-per-share growth and a large, broad mix of products addressing many essential areas of health care. It will generate nearly 40 percent of its sales in high-growth emerging markets, with further expansion expected in the coming years."Abbott will be one of the largest and fastest-growing global diversified medical products companies, with a compelling portfolio of durable growth businesses in medical technology, branded generic pharmaceuticals and nutritionals," said Mr. White. "We will continue to grow our product lines, market share and global presence, especially in emerging markets.""The research-based pharmaceutical company will be a leader in its industry with a strong and sustainable portfolio of specialty medicines and a promising pipeline of future products," said Mr. Gonzalez. "This business has be 바카라전략en delivering market-leading performance and is well positioned for future success."Following are brief profiles of the two companies as their businesses exist today:The Research-Based Pharmaceutical Company- Annual Sales: Ne 바카라전략arly $18 Billion (based on 2011 estimates)- Portfolio: Numerous leading medicines, including: Humira, Lupron, Synagis, Zemplar, Kaletr 바카라전략a, 바카라전략 Creon, Duodopa, Synthroid, Androgel and others.- Pipeline: Advancing pipeline of promising new specialty medicines and formulations, including more than 20 new compounds or indications in Phase 2 or 3 development across such disease states as immunology, chronic kidney disease, Hepatitis C, women's health, oncology, and neuroscience, including Multiple Sclerosis and Parkinson's and Alzheimer's diseases.The Diversified Medical Products Company (Abbott)- Annual Sales: Approximately $22 Billion (based on 2011 estimates)- Portfolio: Market-leading positions in established pharmaceuticals (branded generics outside the U.S.), adult and pediatric nutritionals, core laboratory diagnostics, point of care and molecular diagnostics, and medical devices, including vascular devices, diabetes care and vision care. Abbott w 바카라전략ill have an extensive, broad-based pipeline of new technologies and products.- Global and Emerging Markets Presence: Products in more than 130 countries with nearly 40 percent of sales in emerging markets today; Abbott is the leading pharmaceutical company in India and has a significant and growing presence in many other emerging markets.Transaction DetailsThe transaction is intended to take the form of a tax-free distribution to Abbott shareholders of a new publicly traded stock for the new pharmaceutical company. The expected stock distribution ratio will be determined at a future date.It is expected that the two companies will each pay a dividend that, when combined, will equal the current Abbott dividend at the  바카라전략time of separation.This announcement will not impact Abbott's ongoing earnings-per-share guidance for 2011. The transaction is expected to be completed by the end of next year, but is subject to final approval by the Abbott board of directors, receipt of a favorable ruling from the Internal Revenue Service on the tax-free nature of the transaction, and the effectiveness of a Form 10 registration statement that will be filed with the Securities and Exchange Commission that will include information about the distribution and related matters. Abbott expects 바카라전략 to incur one-time charges related to the transaction during the periods preceding the separation, to be quantified at a later date.Abbott Conference CallAbbott will discuss the transaction on its earnings conference call today at 8 a.m. Central time; 9 a.m. Eastern time. The live Web cast will be accessible through Abbott's Investor Relations Web site at http://www.abbottinvestor.com.About AbbottAbbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs nearly 90,000 people and markets its products in more than 130 countries.Abbott's news releases and other information are available on the company's Web site at http://www.abbott.com.- Private Securities Litigation Reform Act of 1995 -A Caution Concerning Forward-Looking StatementsSome statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995, including the planned separation of the research-based pharmaceutical company from the diversified medical products company and the expected financial results of the two companies after the separation. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements, and there is no assurance as to the timing of the planned separation or whether it will be completed. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors," to our Annual Report on Securities and Exchange Commission Form 10-K for the year ended Dec. 31, 2010, and in the interim reports filed on Form 10-Q for subsequent quarterly periods, and are incorporated by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments.SOURCE: Abbott CONTACT: Media, Melissa Brotz, +1-847-935-3456, or Scott Stoffel, +1-847-935-6902, or Financial, Larry Peepo,+1-847-935-6722, or Tina Ventura, +1-847-935-9390, or Elizabeth Shea,+1-847-935-2211, all of Abbott             까지 내려오는 백 바카라전략발(白髮)과 새하얀 백미(白眉),그리고, 아름답고,  

[blogaarti]

Speciality Drug Distribution Market Key Players, Size, Trends, Opportunities & Growth Analysis 2026

The global speciality drug distribution market is slated to rise between the forecast years of 2022 and 2026 as the prevalence of chronic disease soars. Well-placed federal safety norms and improved diagnostics are shedding light on the severity and complications of chronic conditions, which is expected to bode well for speciality drug distribution market. hepatitis C, Certain forms of cancer, multiple sclerosis, ophthalmology, oncology, rheumatoid arthritis, respiratory conditions, and rare disease categories will be essential to the growth of the global speciality drug distribution market.  

To Read Complete Report of Speciality Drug Distribution Market: https://www.fairfieldmarketresearch.com/report/speciality-drug-distribution-market 

Limited Distribution Drugs to Dominate Specialty Drug Distribution Market

As the name suggests, limited distribution drugs (LDD) are a type of speciality medications available only in a limited number of pharmacies. Although access to them is difficult for patients, they come with myriad benefits. A wide range of speciality drugs go through this channel that is required for complicated and extremely chronic conditions. LDD allows absolute control over distribution, ensuring there is no oversight from manufacturers. In this case, any glitch in medication can be recalled easily and rectified. It also assists in establishing closer patient-pharmacist relationships, which in turn has been an incredible tool in maintaining the authenticity of prescription to arrive at the best treatment outcomes.  

Limited distribution drugs networks also eliminate the possibility of adverse events due to hospitalisation or discontinuation of medication by a patient. As only well-trained clinical staff is responsible for dispensing these medications and supporting patients it brings in a crucial element of consistency and care.

Influx of New Drugs Boosts Market Growth

The approvals for speciality drug approvals have steadily increased over the years as clinical trials and research both receive encouragement. In 2018 alone about 39 new speciality drugs received FDA approval. The pharmacies operating in the market have a solid ongoing pipeline, promising a brighter future for the market. New entries will be a high revenue-generating avenue for the market. The constant conversations between drug manufacturers with PBMs about health plans and changes in government laws about health benefits is expected to create a positive outcome for pricing models for essential therapies that presently cost a premium.  

For instance, Express Scripts, Biomarin, Spark, and Bluebird Bio have an exclusive relationship to facilitate the distribution of expensive gene therapy starting 2020. 

North America to Lead the Way for Global Speciality Drug Distribution Market

As a developed region, North America is expected to hold a lion’s share in the global speciality drugs distribution market. Fairfield Market Research’s upcoming report states that better reimbursement policies, government-based healthcare options, and improved diagnostics are expected to give this regional market an edge over others. Furthermore, the presence of strong players investing in the research and development of drugs is expected to bode well for the region. Asia Pacific too has tremendous potential to grab attention as the region has a huge unmet medical demand.  

Some of the key players operating in the global speciality drug distribution market are Walgreens, ASD Healthcare, Avella, AmerisourceBergen Corporation, Cardinal Health, Besse Medical, D2 Pharma, Centene, DirectRx, Inc., Emory Healthcare, Diplomat Speciality Pharmacy, Excelera, ICORE Healthcare, KloudScript, Marshall Pharmacy, Orsini Speciality Pharmacy, McKesson Speciality Health, and UAB Medicine. 

For More Information Visit: https://www.fairfieldmarketresearch.com/report/speciality-drug-distribution-market

About Us

Fairfield Market Research is a UK-based market research provider. Fairfield offers a wide spectrum of services, ranging from customized reports to consulting solutions. With a strong European footprint, Fairfield operates globally and helps businesses navigate through business cycles, with quick responses and multi-pronged approaches. The company values an eye for insightful take on global matters, ably backed by a team of exceptionally experienced researchers. With a strong repository of syndicated market research reports that are continuously published & updated to ensure the ever-changing needs of customers are met with absolute promptness.

[giarc357]

Why Does Cannabis Work for So Many Different Health Conditions?

By M. Carroll on August 12, 2021Health



The human body continues to amaze scientists. No one has the final answer to anything regarding human physiology, neurology, respiratory, and other systems. Any successful discovery only opens more doors and raises more questions.

Illness has been with us for eons and eons. Some illnesses even evolve and morph. And, since the earliest times, clans and tribes trusted certain people to fix and cure. Until the scientific method came along in the 15th-century, you could not find a universal and transferable solution to problems. The scientific method would launch centuries of development in anatomy, botany, genetics, and more.

But, the scientific method also pushed aside a lot of history, the potions and potables left to priests/priestesses, shamans, wizards, and alchemists. Left to ply their arts on the edge of society, their discoveries are best remembered by a verbal tradition, a history of legends and anecdotes.

As with so many of the right things they did were the discoveries of cannabis, peyote, and other natural resources. Add to that the fact that the pursuit of the scientific method depends on big money, and you find biased motives to keep research into these resources limited.

History makes way for Dr. Mechoulam!

The organic chemistry genius, Raphael Mechoulam, emigrated with his family from Bulgaria to Israel in the late 1940’s. A graduate of the Hebrew University of Jerusalem, he completed his doctoral studies at Rehovot’s Weizmann Institute and postdoctoral work at Manhattan’s Rockefeller Institute. A member of the Israel Academy of Sciences, Dr. Mechoulam is professor at the Hebrew University, an eminent Israeli and world genius.

What he did in the 1960’s was open the treasure that is cannabis and ready it for the kind of scientific inquiry that had left it in the shadows for so long. Basically, he led a team to synthesize THC (Δ9-tetrahydrocannabinol). And, with colleagues, he isolated anandamide and 2-AG, the first endocannabinoids isolated for study.

What comes of this?

Among the body’s many systems is the endocannabinoid system. It runs broadly throughout the human anatomy. It is less independent and differentiated than you might imagine the respiratory system or renal system. It is layered and ubiquitous. Robert Weber explains the endocannabinoid system in a short video.

You might visualize it as a chain of neurons. At the end of each neuron lies a set of receptors that accept transmissions from the previous neuron. In healthy people, the system runs smoothly with the receptors taking just the right amount of transmission and passing it on. If for any reason, like injury or infection, the system is interrupted or upset, the receptors fail at their job, and that registers as pain.

Because of the spread of the endocannabinoid system, that disruption can be felt as a localized disruption like a migraine. Or, it can involve wide-ranging webs as in fibromyalgia and chronic back pain.

Other scientists created the pharmaceutical family of Selective Serotonin Reuptake Inhibitors (SSRI) that fight depression by restoring the harmony in the distribution of serotonin. But, the endocannabinoid system is more complex and less “easily” isolated.

And, because it’s everywhere –

Because of the endocannabinoid system is so present in all parts of the brain and body, it’s connected to more ailments and conditions than other systems. Various state laws recognize as many as 40 conditions as eligible for cannabis treatment.

The Illinois Department of Health lists the following debilitating conditions:

Agitation of Alzheimer’s Disease

Chron’s disease

Hydromyelia

Nail-patella syndrome

Residual limb pain

Spinocerebellar ataxia

HIV/AIDS

CRPS

Interstitial cystitis

Neurofibromatosis

Rheumatoid arthritis

Syringomyelia

ALS

Dystonia

Lupus

Parkinson’s disease

Seizures (epileptic)

Tarlov cysts

Arnold-Chiari Malformation

Fibrous dysplasia

Multiple Sclerosis

Post-concussion syndrome

Severe

fibromyalgia

Tourette’s syndrome

Cancer

Glaucoma

Muscular dystrophy

PTSD

Sjogren’s syndrome

Traumatic brain injury

Causalgia

Hepatitis C

 

Myasthenia gravis

Reflex sympathy disorder

Spinal cord disease

Cachexia/wasting syndrome

Chronic inflammatory demyelinating polyneuropathy

Hydrocephalus

Myoclonus

Post-concussion syndrome

Spinal cord injury

 

 

Cannabis research has taken two directions. The first is to use or emulate cannabis elements or derivatives in the manufacture of medical pharmaceuticals. The British company GW Pharmaceuticals has committed to finding healing solutions in cannabis. Their products include Sativex®, a treatment of spasticity associated with multiple sclerosis and childhood epilepsy has been approved in 29 countries – outside the United States.

GW also has a pipeline that includes Epidiolex® in Phase III testing for treatment of Dravet Syndrome and Lenox-Gastaut Syndrome. Other drugs in Phase I and II include care for epilepsy, autism spectrum disorders, neonatal hypox-ischemic encephalopathy, and glioma.

The University of California – San Diego has established its Center for Medicinal Cannabis Research, where studies are now underway, including:

Effect of Cannabis and Endocannabinoids on HIV Neuropathic Pain

A Randomized, Controlled Trial of Cannabis in Healthy Volunteers Evaluating Simulated Driving, Field Performance Tests and Cannabinoid Levels

A Randomized, Cross-Over Controlled Trial of Dronabinol and Vaporized Cannabis in Neuropathic Low Back Pain

According to CNBC.Com, Oxford University, “The oldest university in England will be teaming up with private equity company, Kingsley Capital Partners who will provide up to £10 million ($12.36 million) in initial investment, which will be funded through its new biopharmaceutical firm Oxford Cannabinoid Technologies (OCT).”

The Associated Press reports, “University of Arkansas for Medical Sciences plan a 5-year study to examine why synthetic compounds — such as K2 and Spice — are more toxic than marijuana.”

And, “a 2015 study published by the National Bureau of Economic Research, a non-partisan think-tank, "[S]tates permitting medical marijuana dispensaries experience a relative decrease in both opioid addictions and opioid overdose deaths compared to states that do not."

The preceding projects are often tied to and funded by pharmaceutical interests which does not diminish their value.

But, the second direction is to study the effects of medical marijuana. Without financial support for such research in the U.S., little is happening in this area. We are left with anecdotal history. It’s not scientific theory, but there is value in real world and real-time experience.

This has been driven lately by the potential of the burgeoning canna-economy. Breeders, farmers, harvesters, and purveyors need verification for the claims their marketing makes. An increasingly populated market will govern economic success as educated and informed consumers. History knows what science needs to prove: why cannabis works for so many different health conditions! 

[jesse-pinkman123]

Sexually Transmitted Diseases (STDs) Treatment Market Forecast Analysis-2027

Sexually Transmitted Diseases Treatment market - Regional Analysis

Geographically, the Sexually Transmitted Diseases Treatment Market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to be dominant market, owing to rising government initiative for disease awareness and implementation of prenatal screening programs. However, Asia Pacific is expected to be fastest growing market for sexually transmitted diseases treatment, due to high incidence of sexually transmitted infections, owing to unprotected sexual practices in the region. For instance, according to Joint United Nations Programme on HIV and AIDS (UNAIDS), Asia Pacific had the second-highest number of people living with HIV in the world i.e. 5.1 million as of 2016, Moreover, China, India, and Indonesia accounts for three quarters of the total people living with HIV in Asia Pacific.

Sexually transmitted disease also known as venereal diseases is a clinical syndrome of infection, acquired and transmitted through sexual activity via body fluids such as semen, vaginal fluid or blood. Causative agent of STD are bacteria, parasites, yeast, and viruses. Symptoms of STDs includes skin rashes, warts, abdominal pain or genital ulcers. STDs are detected by physical examination or assays such as ELISA (Enzyme Linked Immunosorbent Assay), rapid plasma reagin blood test or antibody-absorption blood test. The sexually transmitted disease treatment market is expected to witness high growth in the forecast period (2017 – 2025), due to the factors such as increasing disease burden, governmental initiatives for increasing awareness, growing diagnosis of sexually transmitted diseases, and increasing number of pipeline products by manufacturers for treatment of these diseases.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/2005

Sexually Transmitted Diseases Treatment market – Driver

Increasing sexually transmitted disease burden is fueling growth of the STDs treatment market. Among 20 STDs, the most common are Gonorrhea, Chlamydia, Syphilis, Herpes, Hepatitis (HBV), and Human Immunodeficiency Virus (HIV). For instance, according to Centers for Disease Control and Prevention (CDC), in year 2016, 1,598,354 cases of Chlamydia trachomatis infection were reported in the U.S., corresponding to 497.3 cases per 100,000 in 2015. Furthermore, 468,514 gonorrhea cases were reported for a rate of 145.8 cases per 100,000 population, an increase of 18.5% from 2015. This increasing incidence of STDs is also due to the unprotected sexual practice, which in turn fueling demand for STDs treatment. For instance, according to World Health Organization (WHO), unsafe sex is second most common risk factor for increasing disease burden.

The number of products in pipeline for HIV treatment are high, which is expected to propel growth of the sexually transmitted disease treatment market. For instance, in 2017, GSK and ViiV Healthcare applied in European Medicines Agency (EMA) and US Food and Drug Administration (FDA), for regulatory affiliation for a single-tablet, two-drug regimen of dolutegravir (by ViiV Healthcare) and rilpivirine (by Janssen) used for treatment of HIV-1 infection. Moreover, other drug candidates in pipeline includes – PrEP, PRO140 with ibalizumab, BMS- 955176, which are expected to be launched in the forecast period. Moreover, governments are focusing on funding research and development programs, which is expected to aid in growth of the market. For instance, British Columbia Center for Disease Control sponsored doxycycline (drug) studies for indication of syphilis and other sexually transmitted infection, which is in early phase I clinical trial as of 2016.

Browse Research Report: https://www.coherentmarketinsights.com/ongoing-insight/sexually-transmitted-diseases-stds-treatment-market-2005

Moreover, increasing governmental initiatives to spread awareness through organization of campaigns and free diagnostic camps is also expected to augment growth of the STDs treatment market. For instance, Centers for Disease Control and Prevention (CDC) launched Improving Sexually Transmitted Disease Programs through Assessment, Assurance, Policy Development, and Prevention Strategies, or STD-AAPPS, in 2014. Moreover, in 2018, Thunder Bay Group—HIV / AIDS / hepatitis C education and support services provider— expanded the access of hepatitis C medicine for individuals with level 2 hepatitis C, after negotiating with the provinces and drug manufacturers.

However, growth of the sexually transmitted disease treatment market is expected to be restrained by low rate of screening for diseases and late diagnosis of the disease such as HIV.  

Sexually Transmitted Diseases Treatment market – Competitor

Major players in highly fragmented sexually transmitted diseases treatment market are Merck & Co. Inc., Pfizer INC, GlaxoSmithKline Plc, Vertex Pharmaceuticals, Roche, Gilead Sciences Inc., AbbVie Inc., Johnson & Johnson and Bristol-Myers Squibb. Key players in sexually transmitted disease treatment market are focusing on adopting strategies such as mergers and collaborations for expanding their research for candidate drugs. For instance, in 2017, the drug Zoloflodacin entered into clinical trials, as a result of partnership between Global Antibiotic Research and Development Partnership (GARDP) and Entasis Therapeutics. Moreover, in March 2018, Inovio Pharmaceuticals, Inc. entered into a deal with ApolloBio Corp., which have the exclusive rights for development, manufacturing, and commercialization of VGX – 3100, Inovio’s DNA immunotherapy product for pre-cancer indication.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/2005

About Coherent Market Insights:            

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

mailto:sales@coherentmarketinsights.com

U.S. Office:

Name:  Mr. Shah

Coherent Market Insights 1001 4th Ave,

# 3200 Seattle, WA 98154, U.S.

US :  +1-206-701-6702

UK :  +44-020-8133-4027

JAPAN :  +050-5539-1737